Ectopic expression of human acidic fibroblast growth factor 1 in the medicinal plant, Salvia miltiorrhiza, accelerates the healing of burn wounds by YaQing Tan et al.
Tan et al. BMC Biotechnology 2014, 14:74
http://www.biomedcentral.com/1472-6750/14/74RESEARCH ARTICLE Open AccessEctopic expression of human acidic fibroblast
growth factor 1 in the medicinal plant, Salvia
miltiorrhiza, accelerates the healing of burn
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Background: Healing of burns is a complex process and very few effective treatments exist to facilitate the burn
recovery process. Human acidic fibroblast growth factor 1 (FGF-1) plays an important role in a variety of biological
processes, including angiogenesis, and tissue repair. Salvia miltiorrhiza is widely used in traditional Chinese medicine
as an herb for the treatment of various diseases, including cardiovascular and cerebrovascular diseases, and
traumatic injuries. We present that expression of FGF-1 in S. miltiorrhiza significantly accelerates the healing of burn
wounds.
Results: The human fgf-1 gene was fused with a barley α-amylase signal peptide DNA sequence and driven by a
35S promoter for constitutive expression in transgenic S. miltiorrhiza plants. The highest yield of recombinant FGF-1
obtained from leaves of transgenic S. miltiorrhiza lines was 272 ng/fresh weight. Aqueous extracts from transgenic
S. miltiorrhiza exhibited FGF-1 activity approximately 19.2-fold greater than that of the standard FGF-1. Compared to
the standard FGF-1 or the extracts obtained from non-transgenic plants, it stimulated proliferation of Balb/c 3 T3
mouse fibroblast cells assessed with the standard MTT assay and promoted angiogenesis in the chicken embryo
chorioallantoic membrane (CAM) assay. Topical application of the extract significantly accelerated the burn wound
healing process.
Conclusions: The product appears to retain the biological activity of both FGF-1 as well as the medicinal properties
of the plant. The extracts from transgenic S. miltiorrhiza combines the therapeutic functions of FGF-1 and the
medicinal plant, S. miltiorrhiza. Topical application of the product can reduce the costs associated with extraction,
purification, and recovery.
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Various factors, such as heat, electricity, UV-light, and
chemicals, can cause burns. Although most burns are
not fatal, over 300,000 deaths occur globally each year
as a direct result of burns, with 90% of burn deaths occur-
ring in developing countries [1]. Healing of burns is a
complex process and very few effective treatments exist to
facilitate the burn recovery process. Antibiotics are often* Correspondence: liudehu2006@126.com
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unless otherwise stated.used to prevent or treat infections and skin or synthetic
grafts are used to facilitate the healing process in cases of
third-degree burns [2].
Fibroblast growth factors (FGFs) comprise a large family
genes involved in growth and differentiation. They are
found in both invertebrates and vertebrates [3,4]. FGFs
have been demonstrated to play essential functions in
development, metabolism, and repair of various tissues
and organs. Human FGFs contain 22 family members.
Human FGF-1 is one of the most studied and character-
ized members of the superfamily. FGF-1 has various bio-
logical functions and has been associated with various. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Plant expression construct pBI121-αFGF. The construct
was made in the T-DNA vector, pBI121. The coding region of fgf-1
was fused with an alpha amylase signal (αSP). A Kozak sequence was
inserted before the start codon. Pnos, promoter from nopaline synthase
gene; nptII, neomycin phosphotransferase II gene; 3’nos, nopaline
synthase terminator; p35S, CaMV 35S promoter. LB and RB, left and
right border T-DNA sequence. Hind III, Pst I, Xho I and EcoR I were
restriction enzymes used for cloning FGF-1.
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wound healing [3,4].
FGF-1 is present in various tissues, especially within
the extracellular matrix, however, isolating and purifying
this protein is a complicated and tedious process. Recom-
binant DNA technology has enabled FGF-1 to be pro-
duced in E.coli [5], yeast [6], mammalian cells [7] and
plants [8] for potential medical applications. Most studies
designed to evaluate its effect on wound healing and tissue
regeneration have administered recombinant FGF-1 dir-
ectly to animal [9,10] or human wound sites [10]. Like
other FGFs, however, FGF-1 has low stability and is very
sensitive to degradation by proteases [3,4]. Unfortunately,
recombinant FGF-1 exhibits a very short half-life in vivo
which limits its medical application.
Salvia miltiorrhiza, also known as Danshen, native to
China and Japan, is a traditional Chinese medicinal (TCM)
herb. The extract of its root has been widely used clinically
to treat and prevent diseases, such as cardiovascular dis-
ease, hyperlipidemia, cancer, liver fibrosis and cirrhosis,
etc. [11]. Leaf extract of S. miltiorrhiza also contains con-
siderable amounts of pharmacological compounds even it
is discarded as waste during root harvest. More than sev-
enty compounds from S. miltiorrhiza have been investi-
gated. Three major bioactive compounds, tanshinone-I,
tanshinone-IIA, and cryptotanshinone have been exten-
sively studied and reported to have a variety pharma-
cological activities, including anti-inflammatory [12],
antioxidant [13], antitumor [14] and anti-platelet aggrega-
tion [15]. TCM compendiums indicate that S. miltiorrhiza
reduces blood stasis by promoting blood circulation and
repairing damaged tissues. The use of S. miltiorrhiza to
treat coronary heart disease and hypertension, as well as
for stroke patients, is in clinical phase IV trials (clinical-
trials.gov). However, like many TCM herbs, the precise
mechanism underlying the biological activity of S. miltior-
rhiza still remains to be completely elucidated.
In the present study, FGF-1 was constitutively expressed
in the medicinal plant, S. miltiorrhiza. Presence and
levels of FGF-1 were analyzed by ELISA and Western
blot. Aqueous extracts of transgenic S. miltiorrhiza were
applied directly to fertilized chicken egg embryo chorio-
allantoic membranes (CAM) and to second degree burn
wounds on Sprague Dawley (SD) rats. Results indicated
that the transgenic plants exhibited a both the biological
function of FGF-1 and the medicinal properties of S.
miltiorrhiza. Data indicated that the extract obtained
from the transgenic plants could promote cell prolifera-
tion, speed up the growth of new blood vessels and sig-
nificantly accelerate the burn wound healing process
compared to the use of either FGF-1 or S. miltiorrhiza
alone. The use of the transgenic plant extract also
avoids the complicated process of FGF-1 extraction and
purification.Results
Gene cloning and plant transformation
Human FGF-1 was cloned into the expression vector,
pBI121, with a Kozak consensus sequence inserted be-
fore the start codon and a barley alpha amylase signal
sequence at the 5′ end, driven by a cauliflower mosaic
virus 35S (CaMV35S) promoter (Figure 1) for strong
constitutive expression. At least 120 independent puta-
tive transgenic events were obtained. All putative trans-
formants were analyzed by PCR amplification using P1
and P2 primers. Results indicated that fifty-six of the puta-
tive transformants had the predicted 0.5 kb band.
ELISA and western blot analysis
The level of rFGF-1 produced in the confirmed trans-
genic lines was determined by ELISA. Results revealed
that the yield of rFGF-1 in lines T65, T97 and T117
were131, 146 and 272 ng/g fresh leaf weight, respect-
ively, as calculated by comparison with a standard curve
constructed using commercial FGF-1 (see Additional file 1:
Table S1).
Recombinant human acidic fibroblast growth factor 1
(rFGF-1) protein expression in transgenic lines T65, T97
and T117 was determined by the Western blot analysis
(Figure 2). A positive response using FGF-1 monoclonal
antibody demonstrated that transgenic lines (T65, T97,
and T117) had a 16 kDa band corresponding in size to
standard FGF-1. No band was observed in protein sam-
ples extracted from WT plants. The results of the West-
ern blot also indicated that T117 had a higher level of
expression than T65. It corresponded with the results
obtained in the ELISA assay. Since T117 had the highest
level of rFGF-1, it was examined further. Transgene copy
number in line T117 was determined by Southern blot
analyses (see Additional file 2: Figure S1). Results indi-
cated that there was a single T-DNA copy integrated in
line T117.
Proliferative effects of transgenic S. miltiorrhiza (T-SM) on
cell proliferation in vitro
After 72 h of culture, MTT assay revealed that wild-type
S. miltiorrhiza (WT), standard FGF-1 (S-FGF) and T-SM
Figure 2 Western immunoblotting assay. Standard FGF-1
(Lane 1), rFGF-1 expression in wild type plants (Lane 2), and
transgenic plant lines, T65 (Lane 3), T97 (Lane 4) and T117
(Lane 5). 10 μL of supernatant from each sample was used in
the immunoblotting assay.
Table 1 Enzymatic activity of the recombinant FGF-1 from
transgenic S. miltiorrhiza
FGF-1 content ED50 (dilution) AU/mL U/mg
S-FGF 200 ng/mL 41.5 50 2.5 × 105
T-SM 10 ng/mL 41.47 48 4.8 × 106
Effective dose 50 (ED50) is determined by MTT assay curve using Balb/c 3 T3
cells. The dilution fold is used to determine that compounds are active at that
concentration to proliferate 50% of the cell growth. The enzymatic activity of
recombinant FGF-1 from transgenic S. miltiorrhiza (T-SM) is determined in
terms of AU/mL in relation to a standard human acid FGF-1 (S-FGF) with a
known activity (50 AU/mL). The specific enzymatic activity Units of FGF in
T-SM was calculated as 48 AU/mL (41.47/41.50 × 50 AU/mL), with a conversion of
(1000 × 1000/10 ng) × 48 = 4.8 × 106 U/mg.
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pared to the Saline control (Figure 3). The viability of the
cells decreased when the cells were treated with diluted
concentrations of samples. After the second (42 fold) dilu-
tion, WT showed had no effect on cellular viability. After
the third (43 fold) dilution, the absorbance of T-SM
(0.076 ± 0.0034) was still significantly higher than that of
S-FGF (0.065 ± 0.0026). The results indicated that treat-
ment with T-SM greatly increased the cell proliferation
compared with that of the other groups. The estimated ef-
fective dose (ED50) stimulating 50% of the maximal cell
number response was determined from MTT proliferation
curves. The dilution fold of ED50 for S-FGF and T-SM
were 41.5 and 41.47, respectively. The converted enzyme ac-
tivity of T-SM (4.8×106 IU/mg) was approximately 19.2-
fold greater than that of the standard FGF-1 (2.5 × 105 IU/
mg) (Table 1).Figure 3 MTT assay for Balb/c 3 T3 cell proliferation analysis.
After 72 h treatment, the proliferation rate in the extract of
transgenic S. miltiorrhiza plant (T-SM) was significantly higher
compared to the standard FGF-1 (S-FGF), wild-type plant (WT) and
saline solution ( p ≤ 0.001). Data for 4 replicates and 3 repeats were
averaged, and error bars represent SD.T-SM stimulates angiogenesis in vivo
The CAM assay is widely used to study angiogenesis
in vivo. Our study demonstrated that treatment with ex-
tracts from WT, S-FGF and T-SM all stimulated angio-
genesis (Figure 4). At day 11, a very few large vessels
with only few branching were observed with in the sam-
ples treated with just saline. In comparison to the saline
treatment, a greater number of large vessels and branches
were formed in the WT treatment. T-SM treatment in-
duced a significantly greater number of large vessels and
branches compared to all of the other treatments. Even
though the concentration of T-SM rFGF-1 used in the
CAM assay was 1/18.5 of the S-FGF treatment (≈2.7 ng
vs. 50 ng, respectively), it stimulated more vessels. The
greatest amount of branch formation was also observed
with T-SM-induced angiogenesis in the CAM assay.
T-SM Accelerates wound healing process
Images of burn wounds treated with saline, WT, S-FGF
(FGF-1 1000 ng/wound), and T-SM (rFGF-1 ≈ 2.7 ng/
wound) at 0, 3, 7, 14, and 21 d after administering the
burn treatment are shown in Figure 5. On day 3, shrink-
age of the wounds was observed in all groups. WT and
saline groups had begun to form dark granulation tissue.
In contrast, T-FGF-1 treated wounds appeared smooth
and whitish. FGF-1 treated wounds were also smooth
but exhibited some granulation tissue. On day 7, wounds
in all groups continued to shrink and develop thick
granulation tissue. On day 14, while considerable con-
traction of wounds was observed in all treatments, T-SM
treated wounds began rebuilding healthy granulation tis-
sue. On day 21, the S-FGF and T-SM treated wounds
were almost healed, while WT and saline treated wounds
were still very visible and whitish in appearance. Wound
surface area tracing measurements (Figure 6) did not
identify significant difference among the four treatments
on day 0, 7 and 14 and also revealed that the healing
process appeared normal. On day 21, however, both
T-SM and S-FGF treated wounds were significantly re-
duced (P < 0.01) in wound surface area (0.14 ± 0.06 and
0.21 ± 0.05, respectively) compared to the saline (0.64 ± 0.10)
Figure 4 Extracts from transgenic plant promotes angiogenesis in the CAM assay. A: Saline solution was used as negative control. 5 μL of
aqueous extract from wild-type S. miltiorrhiza plants (WT) and transgenic S. miltiorrhiza (T-SM). S-FGF treatment contained 50 ng of FGF-1 produced in
E. coli and obtained commercially.
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treated wounds were almost completely healed. No differ-
ence in wound surface area was observed between saline
and WT treated burns. Importantly, while the concentra-
tion of FGF-1 in the S-FGF treatment was 1000 ng FGF-1/
wound, it was only ≈ 2.7 ng rFGF-1 in the T-SM treatment.
However, they exhibited a similar ability to accelerate the
wound healing process.
Histopathological assessments of burn wound healing
process
Histopathological analysis of normal tissues and the burn
wound healing process was conducted by sectioning of
tissues and staining with hematoxylin and eosin staining
(H & E). A standard second degree burn wound was
established (see Additional file 3: Figure S2). Normal skin
had an intact cuticle, hair follicles, sebaceous glands, colla-
gen and a prickle cell layer (A and B). Epidermal necroly-
sis was observed 24 h after burn treatment (C and D).
In the dermis, dead cells disintegrated and collagen fi-
bers became disorganized. Hair follicles were also dam-
aged and vasodilation and congestion of the blood vessels
were evident.
On day 7, the saline treated burn wounds exhibited in-
flammatory cells in epidermal necrolysis tissue. An in-
flammatory response in the wound area was not obviousFigure 5 Extracts from transgenic plants accelerate the burn wound h
the dorsal skin of SD rats. The area of the burn wounds was treated with (A
1000 ng of commercial FGF-1, and; (D) 100 μL of aqueous extract from tra
21 after burn injury was administered.(Figure 7). In other treatments, homogeneous necrosis
was evident in the epidermal exudate of burn wounds
but with less inflammatory cells. The inflammatory re-
sponse in the wound area was obvious with an increased
number of inflammatory cells (B, C, D). On day 14, in
contrast to saline treated wounds, the burn wounds in
all other treatments exhibited rapidly growing granula-
tion tissue, including fibroblasts, capillaries, and inflam-
matory cells. In S-FGF and T-SM treated burn wounds,
a greater amount of newly formed epidermis began to
migrate into the wound area (C and D). On day 21, sa-
line treated burn wounds still exhibited a thick surface
layer of dead cells. A large number of inflammatory cells
were also observed with some bleeding near the epider-
mis. An incomplete monolayer of epidermal cells was
also observed. Burn wounds in all the other treatments
exhibited good re-epithelialization. A thicker prickle cell
layer was observed in S-FGF treated wounds than in T-
SM treated wounds. Tissue directly in the wound area
began to form hair follicles and other skin appendages.
T-SM treated wounds exhibited less necrotic tissue com-
pared to all the other treatments.
Discussion
Our studies demonstrated that the medicinal plant, S.
miltiorrhiza, can be used to produce functional humanealing process. Second degree burn wounds were administered on
), 100 μL of saline (B) aqueous extract from wild type plants; (C),
nsgenic S. miltiorrhiza. Photographs were taken on Day 0, 3, 7, 14 and
Figure 6 Burn wound surface assay. Area as evaluated using the transparent tracing method described by Bohannon and Pfaller (1983).
Wounds were treated with either 100 μL of saline, 1000 ng commercial FGF-1, or 100 μL aqueous extract from wild type or transgenic S. miltiorrhiza.
Burn wound area was recorded on day 3 (n = 15), 7 (n = 15), 14 (n = 12) and 21 (n = 9). The data represent the Means ± se. n: rats number for each
treatment. *indicates significant difference (P < 0.01) between the specified treatment and the saline treatment.
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of FGF-1, the transgenic plants also contained natural,
endogeneous, medicinal compounds, such as tanshinone-I,
tanshinone-IIA and cryptotanshinone. The therapeutic ef-
fect of the transgenic plants was significant and greater
than using either FGF-1 or the medicinal plant alone.
Western blot (Figure 2) assays indicated that FGF-1 was
expressed in the transgenic S. miltiorrhiza.
The highest accumulation of recombinant FGF-1 level
in transgenic S. miltiorrhiza was 272 ng/g fresh leave
weight in line T117. We found that topical application
of crude extracts from transgenic S. miltiorrhiza could
enhance angiogenesis and accelerate the burn wound
healing process.
The drawback in using plants to produce recombinant
proteins is that plant cells often recognize the proteinsFigure 7 H&E staining. Cryosections (2 μm thick) stained with hematoxyli
application of different treatments. Samples were taken on day 7, 14 and 2
(WT) S. miltiorrhiza; C: 1000 ng FGF-1; and D: 100 μL saline aqueous extractas foreign and target them for degradation. Since only
the expected single band was observed in the western
blot assay, this indicated that the rFGF-1 in S. miltior-
rhiza had not been subjected to proteolysis. Reports
have suggested that foreign gene expression, and protein
yield in transgenic plants could increase after producing
several generations (T1-T4) of plants from self-pollinated
primary (T0) transgenic lines [16,17]. We selected the line
T117, which has a single transgene integration event as
determined by Southern blot (Additional file 2: Figure S1),
to produce subsequent generations in order to determine
if the yield of rFG-1 in transgenic S. miltiorrhiza can
be increased.
Extracts of non-transgenic S. miltiorrhiza can inhibit
the stickiness of blood platelets and decrease fibrin
[11,15]. The extract from this plant is widely used inn (H) and eosin (E) to examine the burn wound healing process after
1. A: 100 μL of saline; B: 100 μL saline aqueous extract from wild type
from transgenic S. miltiorrhiza. Micrographs were taken at 200×.
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cerebrovascular diseases [11]. One of its compounds,
salvianolic acid, was reported to enhance in vitro angio-
genesis in rat endothelial cells through the up-regulation
of VEGF and VEGF receptors genes that promote cell
growth and differentiation [18]. In the CAM assays, we
also observed that the S. miltiorrhiza treatment pro-
duced more blood vessels (Figure 4). These results indi-
cate that S. miltiorrhiza may facilitate angiogenesis. Very
few studies have reported that S. miltiorrhiza has an ef-
fect on the burn wound healing process. One study indi-
cated that injection of S. miltiorrhiza and ligustrazine
can effectively reduce myocardial damage in patients
with severe burns [19]. Animal studies also indicate that
S. miltiorrhiza enhances the wound healing process
[20,21]. Randomized clinical trial of S. miltiorrhiza sug-
gested that it is effective in reducing skin flap ischaemia
necrosis after mastectomy [20]. S. miltiorrhiza can stimu-
late the cell proliferation and it has the potential to be
used for wounding healing or cosmetic treatment [22]. In
this study, the S. miltiorrhiza treatment stimulated fibro-
blast cell proliferation (Figure 3). The burn wound healing
process is complex. We did not observe that S. miltior-
rhiza treatment of burn wounds reduced burn wound area
compared to the saline treatment (Figures 5 and 6). H&E
staining, however, indicated that S. miltiorrhiza treatment
can promote the formation of new cells and tissues
to accelerate wound re-epithelialization. S. miltiorrhiza
can promote the circulation system in wounded tissue
(Figure 7). It may improve the burn wound healing
process by removing necrotic cells, attenuating the in-
flammatory response and apoptosis [12,21], reducing
oxidative stress [12], and possibly facilitate the repair of
tubular epithelia structures [23].
The function of FGFs in tissue repair, angiogenesis and
wound healing is well documented [3,4]. FGF-1 and
FGF-2 promote cell proliferation and migration, as well
as induce the physical organization of endothelia cells
into blood vessel structures [24,25]. These properties can
facilitate the burn wound healing process. The MTT,
CAM assays, and burn wound healing test used in the
present study also demonstrated that the application of
FGF-1 enhanced cell proliferation and induced a greater
number of new blood vessels and reduced the burn
wound surface area more than treatments in which FGF-1
was absent (Figures 3, 4 and 5). These results were further
supported by the histological analysis. The healing rate in
the S-FGF treated wounds was more rapid compared to
either the saline or WT treated wounds. The healing rate
in S-FGF and T-SM treated burn wounds was similar.
H&E staining revealed less necrosis in T-SM treated
wounds than in S-FGF treated wounds. Approximately
2.7 ng of the rFGF-1 was used in the T-SM treatment
while 1000 ng FGF-1 was used in the S-FGF treatment.This indicates that the T-SM treatment was significantly
more efficient in its effect on angiogenesis and the burn
wound healing process. The FGF-1 used in the S-FGF
treatment was produced in E.coli. Common microbial
hosts such as E. coli can produce high yields of recom-
binant protein but lack the requisite machinery for post-
translational modification required for protein stability
and bioactivity [26]. In contrast, the protein synthesis
process in plants is very similar to animal cells. The struc-
ture and function of rFGF-1 derived from transgenic S.
miltiorrhiza may be more similar to native, human FGF-1
and thus have higher activity than FGF-1 obtained from E.
coli. S. miltiorrhiza exhibits anti-inflammatory [12], anti-
oxidant [13] and anti-bacterial activity [27]. The medicinal
properties of S. miltiorrhiza combined with FGF-1 func-
tions appears to accelerate burn wound healing by im-
proving blood circulation and providing more nutrients
and oxygen to the wound area.
FGFs are readily degradable in vivo, which results in
a loss of biological activity and function [3,4,28,29].
FGF-1 biological activity was maintained in the ex-
tracts obtained from transgenic S. miltiorrhiza and
applied topically to burn wounds. S. miltiorrhiza is a
medicinal plant and contains natural compounds that
also have various pharmaceutical functions. Overex-
pression of fgf-1 in S. miltiorrhiza provides the benefits
of both FGF-1 and the medicinal properties of the
plant, which may enhance its therapeutic effects. Plant
specific glycans can harm humans and injection of re-
combinant plant therapeutic proteins may result in an
immunogenic response in humans [30]. Topical applica-
tion of transgenic S. miltiorrhiza extracts avoids plant-
specific glycosylated immunogenic concerns and reduces
the complex and costly purification and recovery process
associated with the production of therapeutic compounds
in microorganisms.Conclusions
We successfully overexpressed fgf-1 in transgenic S. miltior-
rhiza. Supernatant from homogenated transgenic S. miltior-
rhiza plants promoted angiogenesis and accelerated the
burn wound healing process. The product system com-
bines the therapeutic functions of FGF-1 and the medi-
cinal plant, S. miltiorrhiza. Topical application of the
product can reduce the costs associated with extrac-
tion, purification, and recovery. The yield of rFGF-1
could be further increased by optimizing the gene codon,
targeting the protein to the specific subcellular com-
partments, or selfing of high-expressing lines to obtain
homozygous plants. The mechanism associated with
the enhanced biological activity of S. miltiorrhiza and
FGF-1 combined in the same extract will require fur-
ther study.
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The plasmids, pUC-haFGF (containing fgf-1 gene), pTΩ4A,
the plant expression construct pBI121, and Agrobacterium
tumefaciens LBA4404 are materials maintained in our lab.
Seeds of S. miltiorrhiza were purchased from Shangluo
Northwestern Medical Plant Company of Shaanxi (Shaanxi,
China). Balb/c 3 T3 mouse fibroblast cells were bought
from the Cell Culture Center, Institute of Basic Medical
Sciences of Chinese Academy of Medical Sciences and
School of Basic Medicine of Peking Union Medical College
(Beijing, China). Fertilized eggs were obtained from the
Institute of Animal Sciences (IAS), Chinese Academy of
Agricultural Science (CAAS), Beijing, China. Male
Sprague–Dawley (SD) rats (aged 6 to 7 weeks) were pur-
chased from Vital River Laboratories Company (Beijing,
China). All animal protocols were approved by the CAAS
Institutional Ethics Committee.Plasmid construction
In order to enhance recombinant FGF-1 expression
level, a Kozak consensus sequence was inserted before
the start codon and a barley alpha amylase signal peptide
[31,32] was fused to the FGF-1 sequence for extracellu-
lar targeting of the recombinant FGF-1. Three rounds of
PCR were performed. The first round of PCR used P1
and P2 primers. P1 (forward): 5′-CTTTCTGCCAGCTT
GGCCTCCGGACAAGTTTACAAGAAGCCAAAGTT
GCTTTACT-3′ (Italicized sequences indicate the partial
3′- end alpha amylase signal peptide sequence obtained
from barely (Hordeum vulgare) and P2 (FGF-1 reverse);
5′-AACTCGAGTTAATCAGAAGAAACTGGCAAT-3′
(Xho I site is italicized). PCR product resulting from
the use of the P1 and P2 primers was used as the template
for the second round PCR with P3 and P2 primers. P3
(forward):5′-TCCCTCTCCCTCTTCCTCGTCCTCCTT
GGCCTTTCTGCCAGCTTGGCCTCCGGAC-3′ (Ital-
icized sequences indicate the middle region of the alpha
amylase signal peptide sequence). The second round PCR
product resulting from the use of the P3 and P2 primers
was used as the template for the third round PCR with
P4 and P2 primers. P4 (forward): 5′- AACTGCAG
AACAATGGCGAACAAACATTTGTCCCTCTCCCTC
TTCCTCGTCCTCC (Italicized sequences indicate the
Pst I site and 5′-end partial alpha amylase signal peptide
sequence, respectively. The bold indicates the Kozak
sequence). The third round PCR product was analyzed on
a 1% agarose gel and subcloned into a TA cloning vector.
After sequence verification (TaKaRa, Dalian, China), the
product was digested using Pst I/Xho I and inserted be-
tween the 35S promoter and Nos terminator of pTΩ4A.
The resulting 35S-(fgf-1)-Nos cassette was digested using
Hind III/EcoR I and then inserted into a plant binaryvector, pBI121 using the same sites, to generate the plant
expression construct, pBI121-aFGF.Plant transformation and selection
Transformation of S. miltiorrhiza utilized the method
described by Horschet et al. [33] with modification. The
binary vector pBI121-aFGF described above was intro-
duced into A.tumefaciens strain LBA4404 using the tripar-
ental mating method. The resulting culture was plated on
YEP (Yeast extract 10 g/L, Peptone 10 g/L, NaCl 5 g/L,
pH 7.0) plates containing selective antibiotics (kanamycin
50 mg/L and rifampicin 50 mg/L). A single colony was an-
alyzed by PCR using P1 and P2 primers, inoculated into
50 mL of YEB medium containing kanamycin (50 mg/L)
and rifampicin 50 mg/L, and grown at 28°C, 240 rpm until
the OD600 reached 1.0. The culture was pelleted by centri-
fugation and re-suspended in MS liquid medium to obtain
an approximate OD600 of 0.5. Explants (0.5 cm × 0.5 cm)
were excised from 2- to 3-week-old sterile S. miltiorrhiza
seedlings and immersed for 5 to 8 min in the Agrobacter-
ium suspension described above for 5 to 8 min. The ex-
plants were then blotted on sterile filter paper and plated
on a co-cultivation medium (MS, 6-BA 2.0 mg/L) in the
dark for 2 days at 25°C. After co-culture, the explants were
transferred onto selection medium (MS, 6-BA 1.0 mg/L,
kanamycin 50 mg/L, cefotaxime 400 mg/L). Cultures were
incubated at 25°C/23°C (day/night temperature) with a
16-hr photoperiod. Explants were transferred to fresh se-
lection medium every 2 weeks to generate shoots. Shoots
were then transferred to a rooting medium (1/2 MS, su-
crose 2.0%, kanamycin 30 mg/L) to obtain roots. Plants
were acclimated for two weeks in vermiculite with half
strength MS liquid medium and then transferred to soil.Southern blot analysis of putative transgenic plants
Putative transgenic plants were analyzed by DNA
hybridization. Total leaf genomic DNA was extracted
according to Minas et al. [34]. Thirty μg DNA was
digested overnight with single site EcoR I or Hind III
restriction enzymes. The digested product was run on
a 0.8%agarose gel. Gel denaturation and neutralization
was followed by a routine DNA Southern Blot [35].
The gel was blotted on positively charged nylon mem-
branes by capillary transfer with 20 × SSC following
the protocol described in the instruction manual for
the DIG High Prime DNA labeling and detection kit
(Roche Diagnostics, Indianapolis, USA). DNA fixation,
hybridization and wash procedures also followed the
manufacturer’s instructions. DIG-labeled probe was
amplified with fgf-1 specific primers P1 and P4. Immuno-
logical detection was performed according to the manu-
facturer’s instructions.
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The ELISA procedure was performed according to the
method described in the instruction manual of the Human
FGF-acidic ELISA Construction Kit (Antigenix America,
Huntington Station, USA). Standard FGF-1 produced in
E.coli (Wanxing-Bio, Shanghai, China) was used to create
a series of dilutions (0, 3.125, 6.25, 12.5, 25, 50 and
100 ng/mL) in 1XPBS (phosphate buffered saline) buffer
to construct a standard curve. Total soluble protein ex-
tracts were made by grinding 20 mg of fresh leaf material
in 200 μL1XPBS buffer. The mixture was centrifuged at
12, 000 g for 10 min at 4°C. Recombinant FGF-1 (rFGF-1)
protein present in 100 μL supernatant was loaded in du-
plicate wells of a microtiter plate and the OD650 was ob-
tained. The concentration of rFGF-1 was determined by
comparison with the constructed FGF-1 standard curve.
For immunoblot analysis, 50 mg of leaf disks were
ground in 200 μL of deionizer water. The extract was cen-
trifuged at 12, 000 g for 10 min at 4°C. 100 μL of super-
natant was collected and concentrated to 20 μL at 4°C for
5 min using a vacuum concentrator (SPD1010 SpeedVac
Syetem, Thermo Scientific, USA). 10 μL of the concen-
trated supernatant was separated by 15% SDS-PAGE, and
transferred to a nitrocellulose membrane with an iBlot®
blotting system (Invitrogen). Western blot analysis of
rFGF-1 was performed as described by Li et al. (2012).
FGF-1 antibody (Sino Biological Inc. Beijing, China) was
used as the primary antibody. Nonspecific binding was
blocked by incubation in 3% bovine serum albumin
(BSA) in TBST (25 mM Tris–HCl, pH 7.4, 0.14 mM
NaCl, and 0.05% Tween 20) for 2 h at 4°C. The mem-
brane was washed three times for 10 min each in TBST
and then incubated in streptavidin-HRP for 1 h. The
membrane was then wash three times in TBST and then
stained with 4-Chloro-1-naphthol (4CN) to visualize the
results.
Cellular proliferation
The effect of wild-type S. miltiorrhiza (WT), transgenic
S. miltiorrhiza (T-SM) or standard FGF-1 (S-FGF) on cell
viability and proliferation was examined by thiazolyl blue
tetrazolium bromide (MTT) assay described by Mosman
[36]. Leaf tissue (0.25 g fresh weight) of WT and T-SM
was ground in 0.75 mL of 1XPBS buffer respectively, and
centrifuged at 12,000 g for 10 min at 4°C. The superna-
tants were diluted 5 times in RPMI 1640 medium supple-
mented with 0.4% fetal bovine serum (FBS). The yield of
rFGF-1 in diluted aqueous extract from T-SM was 10 ng/mL
determined by ELISA assay. S-FGF (200 ng/mL, enzyme
activity unit: 50 AU/mL) was used as positive control.
RPMI 1640 medium with 0.4% FBS was used as blank
control. All samples (WT, S-FGF and S-FGF) were 4-fold
serially (4°- to 45- fold dilution) diluted in RPMI 1640
medium with 0.4% FBS.A concentration of 6.5 × 103 BALB/c 3 T3 cells per well
were seeded in a 96-well microplate containing 100 μL of
RPMI 1640 medium with 10% FBS. After 24 h of incuba-
tion in a humidified incubator with 5% CO2 at 37°C, all
the medium was refreshed in 100 μL of RPMI 1640 with
0.4% FBS. The cultures were maintained for another 24 h.
And then, the cells were exposed to 100 μL of sample
solutions prepared previously with 100U/mL penicillin
and 100 μg/mL streptomycin. After 72 h incubation,
25 μL of 5 mg/mL MTT (AMRESCO, USA) was added
to each well. After 5 h treatment with MTT, 120 μL of
50% DMSO was added to the well and mixed thoroughly
with pipette. The plate was shaken at room temperature
15 min. The absorbance of each well was determined at
570 nm using a microplate reader (Bio-rad, USA). Four
replicates from each group were analyzed. The experiment
was repeated 3 times. Results are expressed as mean ±
standard error. Student’s t test was used to evaluate sig-
nificance differences between groups at p < 0.05.
CAM assay
The effect of various extracts on angiogenesis (blood
vessel growth) was analyzed by a CAM assay using
methycellulose disks described by Larger et al. [37]. Each
disk was wetted with 5 μL of aqueous extract from either
non-transgenic, wild-type S. miltiorrhiza (WT) or trans-
genic S. miltiorrhiza (T-SM), plants. 5 μL of a saline so-
lution and 50 ng of standard FGF-1 (S-FGF) were used
as negative and positive controls. 10 μL of 0.5% methyl-
cellulose was dried in a well, 2 mm diameter and
0.6 mm deep, of culture plate. Forty five chick eggs were
cleaned with a formalin solution and then incubated at
37°C and 75% RH. Abnormal embryo development was
verified and the embryos with malformations or dead
embryos were discarded. On day 9 of the incubation
period, previously prepared saline, S-FGF, T-SM, or WT
methylcellulose disks were placed on the CAM. The
treated area was carefully excised after 48 h of incuba-
tion and washed with deionized water. The excised area
was spread on 3MM filter paper and photographed with
a Sony DSLR digital camera.
Burn wound surface area assay on SD rats
Male SD rats were anesthetized using diethyl ether. Their
dorsal hair was shaved as clean as possible and the skin
sterilized using 70% ethanol. A 9-cm by 8-cm square of
dorsal skin was further depilated using 8% sodium sul-
fide. The bare skin was sterilized using 1% povidone
iodine solution and cleaned with 0.9% NaCl. Four circu-
lar (2.5 cm2) second degree burns were produced with
YLS-5Q (Biowill Co, LTD. Shanghai, China) on the dor-
sal skin of each SD rat. The burn device was set at 80°C
and applied for 8 seconds. After surgery, each wound was
treated for 5 min with either 100 μL of saline, S-FGF
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ous extract for 5 min. The wound was then covered with
sterile gauze. After treatment, each rat was housed in an
individual cage, 16 × 16 × 9 cm. The burn area was
treated once for 5 minutes every other day for 21 days.
During the experimental period, all the rats had free ac-
cess to fresh water and pelleted feed. The wound surface
area was determined using the transparent tracing method
described by Bohannon and Pfaller [38]. Wound area =
(7.5 cm × 7.5 cm × paper weight)/0.1604 g. The area of
each wound was recorded on day 3 (n = 15), 7 (n = 15), 14
(n = 12) and 21 (n = 9). Results are expressed as mean ±
standard error. Student’s t test was used to evaluate sig-
nificance differences between groups at p < 0.05.Histological staining
Two rats were sacrificed on the day or one day after the
burn was administered to determine the severity of the
burn. Three rats were euthanized after 7-, 14-, and 21 d
of treatment with the different solutions (Saline, S-FGF,
T-SM and WT). Tissues including and surrounding the
burn wounds were removed and frozen in liquid nitrogen.
Wound tissues were cut and processed into 2-μm thick
cryocut sections. The effect of different treatments on the
wound healing process were determined histologically
using a hematoxylin (H) and eosin (E) staining kit (Huaxia
Bio Co., Beijing, China). The status of the wound was de-
termined by the presence of inflammatory cells, necrotic
cells and tissue, epidermal appendages, granulation tissue,
and angiogenesis. Images were taken in the center of each
histological section at a 200× magnification.Additional files
Additional file 1: Table S1. Analysis of recombinant FGF-1 accumulation
in the selected transgenic S. miltiorrhiza lines. Recombinant FGF-1
accumulation levels in aqueous extract from transgenic lines were analyzed
by ELISA. The yield was calculated by the standard FGF-1 curve (Y = 0.0042X
+ 0.1418). Y is the protein measurement of OD650 in 100 μL of 1XPBS buffer.
FW: fresh weight of the leaf. The detailed method was described in material
and method. Data represents mean of duplicates.
Additional file 2: Figure S1. Southern blot. DNA hybrization assay
using fgf-1 as a probe. Genomic DNA (30 μg) from wild-type (WT) and
the transgenic (T117) plants was digested with either, HindIII or EcoRI
restriction enzymes. Lane 1, wild type. Lane 2–9, transgenic lines. Lane 1,
fgf-1 PCR product; Lane 2, WT/HindIII; Lane 3, WT/EcoRI, Lane 4, T117/HindIII;
Lane 5, T117/EcoRI.
Additional file 3: Figure S2. Deep-second burn degree determined by
H&E analysis. Normal skin had an intact cuticle, hair follicles, sebaceous
glands, collagen and a prickle cell layer (A and B). Epidermal necrolysis
was observed 24 h after burn treatment (C and D). Micrographs were
taken at 200×.Abbreviations
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